GMA 204Alternative Names: GMA204
Latest Information Update: 10 Jan 2017
At a glance
- Originator Gmax Biopharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor inhibitors; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer